Injectable ophthalmic drug recalled for sterility assurance failure
FDA is recalling BSS Plus/Lidocaine Opth 1% injectable syringes manufactured by Pharmacy Innovations due to lack of sterility assurance found during a facility inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA classified this as Class II. The hazard represents a risk of harm in an injectable drug product where sterility is critical, but no illnesses or injuries are reported in the source text.
Plain-English summary
The FDA is recalling BSS Plus/Lidocaine Opth 1% (1 mL syringe) Injectable, a prescription medication manufactured by Pharmacy Innovations in Erie, Pennsylvania. The product has been distributed nationwide in the United States.
The recall is due to lack of assurance of sterility. An FDA inspection of the manufacturing facility revealed insanitary conditions.
Patients and healthcare providers who have this product should not use it and should consult their healthcare provider regarding the recall.
The recalled product
- Product
- BSS Plus/Lidocaine Opth 1% (1ML syringe) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Ophthalmic Injectable
- Hazard
- lack-of-sterility
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221004@47
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateCorlanor ivabradine tablets recalled for presence of foreign substance
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01